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SUMMARY 
 
Background: Karnofsky Performance Scale Index (KPS) is a measure of functional 
status that allows patients to be classified according to their functional impairment. We 
aim to assess if the prior KPS may predict the risk of death among patients with acute 
renal failure (ARF). 
 
Methods: A cohort of 668 consecutive patients who had been admitted in an university-
affiliated hospital between June 2000 and June 2006, and had been diagnosed with 
ARF, were studied. Three hundred and eighty-six patients with ARF who matched at 
least one of the RIFLE (Risk, Injury, Failure, Loss and End stage) criteria on increased 
serum creatinine were included for subsequent analysis. The group was divided into 
four categories, according to different Karnofsky scores measured by a nephrologist 
(≥80, 70, 60 and ≤50). We used an adjusted logistic regression model to assess the 
relationship between the Karnofky score and mortality.  
 
Results: A significant risk of in-hospital mortality within 90 days was observed when 
the other groups were compared with the ≥80 Karnofsky group. Adjusted odds ratios 
were 8.87 (95% confidence interval (CI) 3.03– 25.99), 6.78 (95% CI 2.61–17.58) and 
2.83 (95% CI 1.04–7.68), for Karnofsky groups of ≤50, 60 and 70, respectively. An 
adjusted odds ratio of 1.75 (95% CI 1.37–2.23) was observed for every 10 point 
decrease in KPS score. 
 
Conclusion: Functional status as indicated by the KPS is an independent predictor of 
death in this cohort of patients with ARF. Patients who presented lower scores had 
increased mortality rates. 
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INTRODUCTION 
 
Despite advances in medical care, acute renal failure (ARF) remains a condition with a 
high mortality risk.1–9 Predicting the outcome can help to reassure patients and their 
families, and to address questions of efficiency and quality of care.10 It is therefore 
important to identify which patients may or not obtain benefits with more intensive 
treatments. Many prognostic scoring systems have been formulated to aid physicians to 
calculate outcomes in ARF.10–14 In addition to providing information about individual 
well-being at a given moment, the assessment of functional status could help identify 
those patients at risk for a worse outcome.15,16 It may be quickly and easily quantified 
by the Karnofsky Performance Scale Index (KPS) (Table 1),17,18 by studying the 
patient’s activity, work and self-care. The KPS has been previously validated for 
oncological patients in Spain.19 The scale has been extensively used as an assessment 
tool in oncology since 1948, and it has been gaining interest as an independent risk 
factor for mortality in other clinical settings, as in patients with endstage renal disease20 
or with glomerulonephritis due to systemic small vessel vasculitis.21 A modified version 
has been proposed as being useful in palliative care.22 The possible prognostic role of 
functional status for outcome in ARF has remained unproven, since it has been 
unknown whether coexisting morbidity and other prognostic variables might affect that 
association. The goal of our study was to assess if the Karnofsky score before admission 
to hospital could be considered an independent predictor of mortality in a cohort of 
patients with ARF treated by a nephrologist at a single centre. 
  
 
  
METHODS  
 
Study population 
The University Hospital of Navarra is a tertiary care teaching medical centre with 400 
beds in the city of Pamplona, Spain. Hospital ethics committee approval was obtained. 
A cohort of 668 patients with ARF, who had been admitted at our hospital between 
2000 and 2006, was prospectively studied. We restricted our analysis to patients with 
adequate increment of creatinine to qualify for the RIFLE (Risk, Injury, Failure, Loss 
and End stage) criteria for ARF,23 and who were older than 16 years old. 
 
Definition of the variables 
Functional status before admission was measured through the KPS by one nephrologist. 
Eleven qualifying items were measured, ranging from a score of 0 for death to 100 for 
normal function, higher scores signified better functional status. Recently, the Acute 
Dialysis Quality Initiative (ADQI) workgroup proposed a consensus definition of ARF, 
using a set of criteria called the RIFLE criteria.23 The RIFLE criteria provide a graded 
definition of ARF severity (Risk, Injury and Failure), stratifying patients according to 
relative changes of serum creatinine and urine output. Patients were classified to the 
maximum RIFLE class (Risk, Injury or Failure) according to their creatinine levels 
only. We were unable to collect full information for urine output. The peak creatinine 
was defined as the highest creatinine during their admission. For patients without 
chronic renal failure reported, the baseline creatinine was calculated using the 
Modification of Diet in Renal Disease (MDRD) equation,24 as recommended by the 
ADQI,23 assuming a glomerular filtration rate of 75 mL/min per 1.73 m2. For patients 
with a history of renal failure, the baseline creatinine was defined as the one measured 
at hospital admission. Demographic data, aetiology of ARF, currently comorbid 
conditions and laboratory data were all prospectively collected. Comorbid conditions 
were used to assess the severity of illness, that was measured through Liano score 
(0.032 x age in decades - 0.086 x male gender - 0.109 x nephrotoxic + 0.109 x oliguria 
+ 0.116 x hypotension + 0.122 x jaundice + 0.150 x coma - 0.154 x consciousness + 
0.182 x assisted respiration + 0.210).10 The difference between serum creatinine value 
obtained at the time of the nephrology consultation and the baseline value was 
calculated and expressed in percentage (%): Relative creatinine change (%) = 
[(creatinine when nephrologist saw the case - basal creatinine)/basal creatinine] x 100. 
Food intake was defined as the caloric ingestion in the previous days, and this was 
classified as ‘appropriate’ when it was optimal, ‘mild malnutrition’ when it had been 
inadequate for less than 3 days, ‘moderate malnutrition’ when it had been inadequate 
between 3 and 7 days, and ‘severe malnutrition’ when it had been inadequate for more 
than 7 days. The patients’ clinical status and treatment for ARF were recorded daily. We 
continued follow up to study the mortality at 90 days from the beginning of nephrology 
consultation. 
 
Serum creatinine concentration was quantified using the kinetic Jaffe assay. 
All cases were treated during the admission at our hospital by the same nephrologist and 
all the data were gathered by the same observer. 
The primary outcome variable was in-hospital mortality within 90 days. 
 
Statistical analysis 
Our population was divided into four categories regarding four Karnofsky scores that 
might be clinically significant and to facilitate the statistical analysis (≥80, 70, 60 and 
≤50). The reason for selecting four Karnofsky categories was mainly because they 
discriminate between four performance statuses that might be useful in the clinical 
practice. The score ≥80 shows patients who are able to carry on normal activity; the 
score 70 shows patients who, despite the inability for normal activity, can take care of 
themselves; the score 60 shows an important difference in means of self-care, patients 
need some kind of assistance, though occasional; while the score ≤50 has particular 
importance because it shows patients who need frequent medical care and assistance. 
 
We considered the Karnofsky scoring before the hospital admission as the exposure 
variable. Non-conditional logistic regression models were fitted to assess the 
relationship between the Karnofsky scoring and the risk of in-hospital mortality. Odds 
ratios (OR) and their 95% confidence intervals (CI) were calculated considering the 
group of Karnofsky scores of ≥80 as the reference category. 
 
Continuous variables were expressed as medians (and interquartile ranges), and 
compared using ANOVA test. We fitted a crude model (univariate, i.e. without any 
adjustment), an age and gender model, and a multivariate-adjusted model including the 
following variables: Liano scoring, percentage of the difference between serum 
creatinines, prior food intake, whether patients were oncological or not, treatment of 
ARF and RIFLE classes selected by the descriptive analysis of potential confounders. 
The Liano scoring includes in its equation the variables for nephrotoxicity, oliguria, 
hypotension, jaundice, mental status and assisted respiration. Categorical variables were 
expressed as proportions and compared with the chi-squared test. We evaluated all first-
order multiplicative interactions (effect modifications) through product terms. The area 
under the receiver operating characteristic (ROC) curve was calculated to assess the 
performance of the model.25
We analysed overall survival at 90 days across groups using the Kaplan–Meier 
methods, and tested differences between groups using the log–rank test. The time of 
origin was the date when the nephrology consultation started. The event defined was 
death, whereas those cases alive at the end of follow up and those lost to follow up were 
censored at their last observation. 
 
All P-values presented are two-tailed, P < 0.05 was considered statistically significant. 
Statistical analyses were conducted using SPSS version 10.0.7 (SPSS Inc., Chicago, IL, 
USA). 
  
 
RESULTS 
 
We evaluated 668 patients. Of these, 219 were excluded because they failed to fulfil the 
RIFLE criteria for serum creatinine values and were not oliguric; 28 presented oliguria 
(but it could not be measured on a 6 h basis) but did not fulfil the creatinine criteria; five 
patients were under 16 years old; and 30 patients had incomplete records. So, 386 
patients remained. They were divided into four groups according to Karnofsky scores 
(≥80, 70, 60 and ≥50). Demographics and baseline clinical characteristics are shown in 
Table 2. The groups were similar in proportions of diabetic, surgical and known chronic 
renal failure patients. They were also similar in terms of age, gender, causes of ARF and 
basal serum albumin. The lower Karnofsky score presented a higher mortality rate. 
There were some significant differences between the groups of Karnofsky scores that 
could be relevant in the clinical setting: The lower groups showed higher previous 
increment of serum creatinine (P = 0.013), worse Liano scores and some elements from 
its equation, lower basal haemoglobin, more impaired prior to food intake, lesser 
proportion of oncology patients, and were given more invasive treatment. The Liano 
scoring includes in its equation the variables for nephrotoxicity, oliguria, hypotension, 
jaundice, mental status, and assisted respiration. Higher mortality rates were presented 
in those groups with higher increments of creatinine, worst Liano scoring, lesser levels 
of haemoglobin, impaired prior food intake or more aggressive treatment. Adjustment 
for covariates was performed. Results of the multiple-variable logistic regression 
analyses examining the impact of the different Karnofsky scores for in-hospital 
mortality is shown in Table 3. We adjusted for potential confounders (age, sex, 
percentage of difference between serum creatinines, Liano scoring, RIFLE classes, food 
intake, basal haemoglobin, oncological patients and treatment). Patients with scores of 
≤50, 60 and 70 presented adjusted ORs of 8.87 (95% CI 3.03–25.99), 6.78 (95% CI 
2.61–17.58) and 2.83 (95% CI 1.04–7.68), respectively, compared with those with 
scores of ≥80. The OR for mortality associated with every 10 points of KPS decrease 
was 1.75 (95% CI 1.37–2.23) (Table 4). 
 
ROC curves analyses were calculated (Fig. 1). The area under the curve was 0.701. 
We analysed the short-term survival. According to the Kaplan–Meier plot, the lower 
Karnofsky scores also presented a statistically significant higher mortality rate in the 
period between the nephrology consultation and 90 days (Fig. 2) compared with 
Karnofsky scores of ≥80 (log–rank test = 0.001) (30, 52, 17 and 7 deaths for Karnofsky 
groups of ≤50, 60, 70 and ≥80, respectively). Most of the deaths (28, 38, 17 and 3 
deaths for Karnofsky groups of ≤50, 60, 70 and ≥80, respectively) occurred during the 
first 60 days of follow up. 
 
 
DISCUSSION 
 
This study involved a cohort of non-oncological and oncological patients and sought to 
examine the relationship between the prior functional status with the risk of mortality in 
ARF. The KPS has been regarded as the gold standard measurement of performance 
status in cancer, but it has demonstrated also to be useful in other clinical settings.20–22 
We found that Karnofsky scoring had an independent influence on mortality in this 
cohort. Comparing Karnofsky scores, patients with counts of ≤50, 60 and 70 had rates 
of in-hospital mortality of 48.4%, 39.7% and 21.6%, respectively, versus rates of 7.7% 
among patients with the highest Karnofsky scores (≥80). We believe it is important to 
note that a relative increment risk for mortality of 75% was observed for every 10 points 
of KPS decrease, after adjusting for other comorbility factors. Although we cannot 
conclude what the causes of the poorer functional status were presenting all the patients’ 
similar ages, we suspect that common pathological conditions as obesity, chronic 
obstructive pulmonary disease, chronic pain or cardiovascular diseases might have been 
involved. 
 
The association between functional status and mortality might reinforce the common 
belief that frail patients do poorly when they suffer a serious illness. Measurement of 
KPS presented at home before hospital admission may be useful. It could improve the 
prediction of the risk of death among patients with ARF. 
 
Because of heterogeneous nature of ARF, it was important to adjust for the severity of 
illness26 with Liano scoring, and for the acute kidney injury using the RIFLE criteria. 
We have chosen the Liano score because of its ability to discriminate mortality from 
survival and its ability to calibrate the observed mortality rate with the expected 
mortality in ARF.7,26,27 Adjusting the severity of illness and using the RIFLE criteria 
will allow more meaningful comparisons in future studies on ARF,6,23,26 and is one of 
the main strengths of this study. Patients did not do worse because they had more severe 
ARF. Those patients with the same RIFLE class and Liano scores, but higher KPS, 
presented lower mortality rates. 
 
It is of interest to point out that 217 patients from the original population would not 
have been diagnosed with ARF according to the RIFLE criteria. They did not present 
oliguria or enough creatinine increment, but were diagnosed of ARF according to other 
criteria at that time. 
 
The ROC curve showed an area of 0.701. The conventional threshold of 0.7 has been 
typically considered satisfactory for clinical use.28 
 
There are several limitations to this study. As an observational single centre study, the 
results identified and described the association between KPS and mortality only. These 
results should be validated with further investigations. With larger numbers and from 
several centres the CIs would decrease in range. Nevertheless, the trend towards 
increased mortality is strong. We believe that this study may prompt larger studies. 
Selection bias may have influenced the results; however, objective data were collected 
by a single investigator following strict criteria, and reviewing the data. Urine output 
data were not available; therefore, it was not possible to estimate the RIFLE criteria 
according to this value. We started to collect the data before the RIFLE criteria was 
formulated, and most of the ward patients had no urine output measured on a six-hourly 
basis. We assume that we might underestimate some cases according to the RIFLE 
criteria. When those excluded oliguric patients (n = 28) were included to the analysis 
into another RIFLE category, an increase of our estimates occurred in the multivariate 
model (OR 10.52, 95% CI 3.78–29.27; OR 8.35, 95% CI 3.24–21.53; OR 3.09, 95% CI 
1.13–8.41, for Karnofsky groups of ≤50, 60 and 70, respectively). Thus, 
misclassification of this covariate would most likely bias the ORs towards the null 
value. Although we cannot rule out the possibility of residual confounding, it is not 
likely that the strong association found could be explained by such a residual 
confounding. Moreover, we adjusted for potential risk factors for mortality among ARF 
patients. 
 
We should concede that a limited but indetermined number of patients might have been 
readmitted after hospital discharge. In that situation, they were included in the cohort as 
new patients. Their KPS and other variables were measured again. 
 
We calculated the MDRD equation to obtain a baseline serum creatinine in patients with 
no previous history of renal failure because a true baseline is often unknown. We solved 
the equation assuming a GFR of 75 mL/min per 1.73 m2, which has been reported to 
estimate a lower limit of a normal GRF.4,6,23 The MDRD formula may be less accurate 
at normal GFR, resulting in overdiagnosis of ARF; however, it is a commonly used test 
in clinical settings where ARF is a concern. The MDRD also has the advantage of not 
requiring body weight data.29 We analysed mortality within 90 days. It could be argued 
that all-cause mortality at longer time is unrelated to. Considering 90 days of follow up, 
the KPS remained significantly associated with mortality. These findings agree with 
previous reports and recommendations about optimal follow-up time in patients with 
established ARF.23,30,31 Unfortunately, discharged patients were not followed up within 
that time period, so we can only present in-hospital mortality rates. 
 
This study does not provide any direct improvement in the treatment of ARF. However, 
it gives more information about the utility of measuring KPS as an inexpensive, 
noninvasive and independent prognosis tool to identify highrisk ARF patients. It also 
strengthens the importance of improving the functional status in the oncology and 
general population. The unchanged mortality rates of ARF over the past years might 
have been affected by the constant increment of frailer patients, despite technical 
advances. 
 
 
CONCLUSION 
 
In this cohort of patients, the lower scores for the KPS were strongly associated with 
higher risk of death, independent of ARF severity, comorbid illnesses and other possible 
confounders. The use of this simple and rapid scale at the start of the treatment could 
aid clinicians to improve the knowledge of the risk profile of every patient with ARF. 
Our findings highlight the importance of functional status on clinical outcomes in this 
disease. Assessment of functional status should be taken into account to compare 
patients in future clinical studies, and adjust for it in the analysis when necessary. 
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Table 1. Karnofsky Performance Scale Index (KPS) 
Score (category) Karnofsky 
100 Normal; no complaints; no evidence of disease. 
90 Able to carry on normal activity; minor signs or symptoms. 
80 Normal activity with effort; some signs or symptoms of disease. 
70 Care for self; unable to carry on normal activity or to do active work. 
60 Requires occasional assistance but is able to care for most of his needs. 
50 Requires considerable assistance and frequent medical care. 
40 Disabled; requires special care and assistance. 
30 
Severely disabled; hospitalization 
necessary; active supportive treatment is 
necessary. 
20 Very sick; hospitalization necessary; active supportive treatment is necessary. 
10 Moribund; fatal processes progressing rapidly. 
0 Dead. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Table 2. Demographics and baseline clinical characteristics of patients 
Variables* Karnofsky≤50(n = 62) 
Karnofsky=60
(n = 136) 
Karnofsky=70 
(n = 97) 
Karnofsky≥80
(n = 91) P-value
Oncology patients (%) 32.3 44.9 39.2 54.9 0.021 
Mortality (%) 48.4 39.7 21.6 7.7 <0.001 
Increase of Creatinine#: median % 
(IQR) 92.99 (134.83) 122.99 (174.43) 97.68 (207.31) 66.20 (142.86) 0.013 
Age: median years (IQR) 60.50 (19.75) 65.00 (17.00) 63.00 (19.00) 59.00 (22.00) 0.055 
Male gender (%) 71.0 69.1 64.9 73.6 0.80 
Surgical (%) 25.6 19.8 30.8 29.9 0.20 
RIFLE criteria (%)     0.05 
Risk 24.2 14.7 18.6 33.0  
Injury 30.6 27.9 25.8 29.7  
Failure 45.2 57.4 55.7 37.4  
Liano scoring: median score (IQR) 0.40 (0.36) 0.30 (0.33) 0.25 (0.30) 0.19 (0.20) <0.001 
Basal serum albumin (mg/dL): median 
(IQR) 2.4 (1.1) 2.4 (1.0) 2.6 (1.0) 2.6 (0.8) 0.13 
Basal haemoglobin (g/dL): median 
(IQR) 10.15 (3.35) 10.50 (3.10) 10.70 (3.48) 11.40 (3.13) 0.036 
Patients with history of chronic renal 
failure (%) 21.0 26.5 24.7 20.9 0.75 
Diabetic (%) 6.5 8.8 6.2 8.8 0.83 
Aminoglycoside use (%) 21 16.9 6.2 9.9 0.009 
Radiocontrast procedure (%) 1.6 16.2 8.2 22.0 0.007 
Hypotension (%) 53.2 39.7 37.1 25.3 0.001 
Oliguria (%) 43.5 51.5 40.2 19.8 <0.001 
Jaundice (%) 50.0 32.4 24.7 18.7 <0.001 
Coma (%) 17.7 9.6 7.2 4.4 0.006 
Consciousness (%) 77.4 83.8 86.6 86.8 0.123 
Mechanical ventilation (%) 29.0 19.1 19.6 15.4 0.075 
Nephrotoxicity (%) 40.3 36.8 36.1 56.0 0.030 
Causes of acute renal failure (%)     0.38 
Pre-renal 91.9 77.9 81.4 76.9  
Intrinsic renal 8.1 14.7 13.4 20.9  
Post-renal 0.0 2.2 4.1 1.1  
Other causes 0.0 5.1 1.0 1.1  
Treatment of acute renal failure (%)     <0.001 
Non-dialytic 64.5 68.4 70.1 84.6  
Intermittent haemodialysis 0.0 5.9 5.2 5.5  
Continuous replacement therapy 24.2 17.6 21.6 9.9  
Both (intermittent + continuous) 11.3 8.1 3.1 0.0  
Food intake (%)     <0.001 
Optimal nutrition 11.3 26.0 26.4 51.2  
Mild malnutrition 19.4 18.3 17.2 20.2  
Moderate malnutrition 22.6 24.4 39.1 22.6  
Severe malnutrition 46.8 31.3 17.2 6.0  
*Continuous variables are expressed as median and interquartile range. #Creatinine increase (%) = [(creatinine when 
nephrologist saw the case - basal creatinine)/basal creatinine] x 100. IQR, interquartile range. 
Table 3. ORs and 95% CIs of in-hospital mortality for different Karnofsky scores 
Karnofsky scores
 ≥80 
n = 7 (7.7%) 
70 
n = 21 (21.6%)
60 
n = 54 (39.7%) 
≤50 
n = 30 (48.4%) 
P for 
trend 
Crude OR (95% CI) 1.00 (Ref.) 3.32 (1.34–8.25) 7.81 (3.36–18.17) 11.12 (4.44–27.84) <0.001 
Age- and sex-adjusted 
OR (95% CI) 1.00 (Ref.) 3.62 (1.44–9.08) 8.96 (3.80–21.14) 12.11 (4.79–30.65) <0.001 
Multivariate-adjusted 
OR* (95% CI) 1.00 (Ref.) 2.83 (1.04–7.68) 6.78 (2.61–17.58) 8.87 (3.03–25.99) <0.001 
*Adjusted for age, sex, relative increment of serum creatinine, Liano scoring, RIFLE classes, food 
intake, basal haemoglobin, oncology patients and treatment of acute renal failure. CI, confidence 
interval; OR, odds ratio. 
 
 
 
 
 
 
 Table 4 ORs and 95% CIs of in-hospital mortality for every 10-point 
Karnofsky score  
 Crude OR (95% CI) 1.83 (1.50–2.24) 
Age- and sex-adjusted OR (95% CI) 1.86 (1.52–2.28) 
Multivariate-adjusted OR* (95% CI) 1.75 (1.37–2.23) 
 
 
 
 
 
 *Adjusted for age, sex, relative increment of serum creatinine, Liano 
scoring, RIFLE classes, food intake, basal haemoglobin, oncology 
patients and treatment of acute renal failure. CI, confidence interval; 
OR, odds ratio. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Receiver operating characteristic curve analysis. Area: 0.701. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Cumulative survival (Log–rank test <0.001). Karnofsky groups: – – ≥80;—
70; · · · · 60; — · ≤50. 
